StageZero Life Sciences Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for detection of diseases and for personalized health management, with a focus on cancer-related indications. Its products includes Sentinel Principle, and ColonSentry. The company was founded by Choong-Chin Liew and K. Wayne Marshall on February 20, 1997 and is headquartered in Richmond Hill, Canada.
Sector:
Health Technology
Industry:
Medical Specialties
Employees:
N/A
Frequently Asked Questions
What is Market Cap of StageZero Life Sciences Ltd?
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. StageZero Life Sciences Ltd market cap is $630,100.00.
What is the 52-week high for StageZero Life Sciences Ltd?
52 week high is the highest price of a stock in the past 52 weeks, or one year. StageZero Life Sciences Ltd 52 week high is $0.0727 as of April 05, 2026.
What is the 52-week low for StageZero Life Sciences Ltd?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. StageZero Life Sciences Ltd 52 week low is $0.0005 as of April 05, 2026.
What is StageZero Life Sciences Ltd stock price today?
StageZero Life Sciences Ltd stock price today is $0.0051.
What was StageZero Life Sciences Ltd stock price yesterday?
StageZero Life Sciences Ltd stock price yesterday was $0.0005.
What is the 50-day moving average of StageZero Life Sciences Ltd?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. StageZero Life Sciences Ltd 50-day moving average is $0.0012.